Viewing data from:

BEPOTASTINE BESILATE

ANDA

BEPOTASTINE BESILATE | A206220 | MYLAN PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: BEPREVE(TE code: AT)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$11.56

per ml

Lowest NADAC/Unit

$8.56

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378705535BEPOTASTINE 1.5% EYE DROP	$11.56	ML	Generic	—	2026-06-17
00378705567BEPOTASTINE 1.5% EYE DROP	$8.56	ML	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain5 active DMFs2 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

UBE CORPBEPOTASTINE BESILATE

DMF 199662006

BAL PHARMA LTDBEPOTASTINE BESILATE

DMF 273502013

BAL PHARMA LTDBEPOTASTINE BESILATE

DMF 273862013

ICROM SRLBEPOTASTINE BESILATE

DMF 274652013

MSN LABORATORIES PRIVATE LTDBEPOTASTINE BESILATE [ROUTE CODE - "BB"]

DMF 280122014

MEDICHEM MANUFACTURING (MALTA) LTDInactiveBEPOTASTINE BESILATE

DMF 271702013

MEDICHEM MANUFACTURING (MALTA) LTDInactiveBEPOTASTINE BESILATE

DMF 289012014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 1.5%

0 patents0 exclusivities▴

SOLUTION/DROPS;OPHTHALMIC | Approved: Mar 18, 2019

No patent or exclusivity listings for this strength.